Profile data is unavailable for this security.
About the company
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
- Revenue in AUD (TTM)5.76m
- Net income in AUD-86.40m
- Incorporated1984
- Employees1.00
- LocationBotanix Pharmaceuticals LtdSuite 3, 41-47 Colin Street, West PerthPERTH 6005AustraliaAUS
- Phone+61 86285-0083
- Fax+61 86210-1153
- Websitehttps://botanixpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inoviq Ltd | 959.32k | -6.93m | 46.46m | 85.00 | -- | 2.20 | -- | 48.43 | -0.0623 | -0.0623 | 0.0086 | 0.1497 | 0.0478 | 3.73 | 0.6725 | -- | -34.52 | -43.01 | -37.36 | -45.87 | 87.45 | 89.08 | -722.62 | -1,543.44 | 5.72 | -- | 0.022 | -- | 21.17 | 57.69 | -5.77 | -- | -- | -- |
| Medical Developments International Ltd | 39.06m | 94.00k | 51.26m | 68.00 | 541.67 | 0.9302 | 15.55 | 1.31 | 0.0008 | 0.0008 | 0.3469 | 0.4891 | 0.6221 | 1.06 | 5.31 | -- | 0.1497 | -16.68 | 0.1738 | -18.92 | 75.35 | 72.70 | 0.2407 | -47.08 | 3.33 | -- | 0.0349 | -- | 17.82 | 11.30 | 100.23 | -24.33 | -34.91 | -- |
| Neurizon Therapeutics Ltd | 1.88m | -16.59m | 64.04m | 52.00 | -- | 16.51 | -- | 34.03 | -0.0334 | -0.0334 | 0.0038 | 0.0056 | 0.2431 | -- | 203.57 | -- | -214.34 | -65.69 | -254.22 | -74.86 | -- | -- | -881.68 | -368.00 | -- | -- | 0.00 | -- | -- | -- | -86.45 | -- | -44.79 | -- |
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 77.97m | 14.00 | -- | 1.16 | -- | 21.46 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 91.27m | 30.00 | 440.86 | 19.35 | 199.88 | 4.94 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Vita Life Sciences Ltd | 85.60m | 9.31m | 142.01m | 124.00 | 15.71 | 2.76 | 29.33 | 1.66 | 0.1655 | 0.1655 | 1.52 | 0.9427 | 1.20 | 2.30 | 6.65 | -- | 13.05 | 15.71 | 17.96 | 22.24 | 60.34 | 59.82 | 10.87 | 12.15 | 2.21 | -- | 0.0409 | 47.99 | 8.28 | 13.37 | -3.26 | 22.87 | 29.67 | 21.67 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 170.62m | -- | -- | -- | -- | 22.14 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 5.85m | -9.99m | 205.76m | 50.00 | -- | 10.79 | -- | 35.17 | -0.024 | -0.024 | 0.014 | 0.0454 | 0.188 | 0.5663 | 0.9444 | -- | -32.10 | -26.74 | -39.68 | -32.74 | 79.08 | 75.64 | -170.77 | -259.38 | 3.95 | -- | 0.1122 | -- | -40.04 | -2.25 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 413.01m | -90.07m | 212.86m | 450.00 | -- | 0.5749 | -- | 0.5154 | -1.14 | -1.19 | 5.22 | 4.56 | 0.3828 | 2.57 | 2.42 | 917,797.80 | -8.35 | -15.32 | -11.61 | -20.87 | 61.06 | 53.04 | -21.81 | -64.51 | 1.16 | -- | 0.1003 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 221.64m | 1.00 | -- | 2.71 | -- | 38.50 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Clinuvel Pharmaceuticals Ltd | 95.02m | 36.17m | 532.13m | 16.00 | 14.77 | 2.21 | 14.25 | 5.60 | 0.7177 | 0.7177 | 1.89 | 4.80 | 0.3779 | 0.1857 | 3.54 | -- | 14.39 | 17.33 | 16.06 | 19.40 | 98.10 | 101.95 | 38.07 | 38.23 | 9.34 | -- | 0.0022 | 7.22 | -0.5085 | 23.46 | 1.50 | 19.17 | -19.60 | 14.87 |
Data as of Feb 13 2026. Currency figures normalised to Botanix Pharmaceuticals Ltd's reporting currency: Australian Dollar AUD
9.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Copia Investment Partners Ltd.as of 27 Aug 2025 | 102.10m | 5.18% |
| Vanguard Investments Australia Ltd.as of 31 Dec 2025 | 34.69m | 1.76% |
| Netwealth Investments Ltd.as of 27 Aug 2025 | 28.54m | 1.45% |
| Antares Capital Partners Ltd.as of 30 Nov 2025 | 13.67m | 0.69% |
| Fideuram Asset Management (Ireland) DACas of 31 Dec 2025 | 8.07m | 0.41% |
| BlackRock Asset Management North Asia Ltd.as of 31 Oct 2025 | 5.74m | 0.29% |
| BlackRock Investment Management (Australia) Ltd.as of 06 Feb 2026 | 1.21m | 0.06% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 995.27k | 0.05% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 559.58k | 0.03% |
| DFA Australia Ltd.as of 31 Dec 2025 | 290.78k | 0.02% |
More ▼
Data from 30 Nov 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
